CA2054325A1 - Antisense oligonucleotides for treatment of cancer - Google Patents

Antisense oligonucleotides for treatment of cancer

Info

Publication number
CA2054325A1
CA2054325A1 CA002054325A CA2054325A CA2054325A1 CA 2054325 A1 CA2054325 A1 CA 2054325A1 CA 002054325 A CA002054325 A CA 002054325A CA 2054325 A CA2054325 A CA 2054325A CA 2054325 A1 CA2054325 A1 CA 2054325A1
Authority
CA
Canada
Prior art keywords
antisense oligonucleotides
cancer
treatment
animals
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002054325A
Other languages
French (fr)
Other versions
CA2054325C (en
Inventor
Yoon S. Cho-Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foryou Corp
Original Assignee
Yoon S. Cho-Chung
Foryou Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoon S. Cho-Chung, Foryou Corporation filed Critical Yoon S. Cho-Chung
Priority to CA002488792A priority Critical patent/CA2488792A1/en
Publication of CA2054325A1 publication Critical patent/CA2054325A1/en
Application granted granted Critical
Publication of CA2054325C publication Critical patent/CA2054325C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Abstract

RI.alpha. antisense oligonucleotides ana pharmaceutical compositions thereof are disclosed. Methods for treating certain cancers in animals comprising administering to animals an effective amount of an RI.alpha.
antisense oligonucleotide, or a pharmaceutical composition thereof, are also disclosed.
CA002054325A 1990-11-02 1991-10-28 Antisense oligonucleotides for treatment of cancer Expired - Fee Related CA2054325C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002488792A CA2488792A1 (en) 1990-11-02 1991-10-28 Antisense oligonucleotides for treatment of cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US60711390A 1990-11-02 1990-11-02
US607,113 1990-11-02
US68019891A 1991-04-05 1991-04-05
US680,198 1991-04-05
US702,163 1991-05-20
US07/702,163 US5271941A (en) 1990-11-02 1991-05-20 Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002488792A Division CA2488792A1 (en) 1990-11-02 1991-10-28 Antisense oligonucleotides for treatment of cancer

Publications (2)

Publication Number Publication Date
CA2054325A1 true CA2054325A1 (en) 1992-05-03
CA2054325C CA2054325C (en) 2005-03-15

Family

ID=27416969

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002488792A Abandoned CA2488792A1 (en) 1990-11-02 1991-10-28 Antisense oligonucleotides for treatment of cancer
CA002054325A Expired - Fee Related CA2054325C (en) 1990-11-02 1991-10-28 Antisense oligonucleotides for treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002488792A Abandoned CA2488792A1 (en) 1990-11-02 1991-10-28 Antisense oligonucleotides for treatment of cancer

Country Status (9)

Country Link
US (3) US5271941A (en)
EP (3) EP0785252B1 (en)
KR (1) KR0171210B1 (en)
AT (2) ATE194383T1 (en)
CA (2) CA2488792A1 (en)
DE (2) DE69127175T2 (en)
DK (2) DK0785252T3 (en)
ES (2) ES2104644T3 (en)
GR (2) GR3024673T3 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5646267A (en) * 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US5359052A (en) * 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US6995146B2 (en) * 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
CA2158347A1 (en) 1993-03-26 1994-10-13 Renato Baserga Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5639872A (en) * 1993-07-27 1997-06-17 Hybridon, Inc. Human VEGF-specific oligonucleotides
EP1584682B1 (en) * 1993-09-20 2009-07-15 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5618709A (en) * 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6645943B1 (en) 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US20050054600A1 (en) * 1995-08-17 2005-03-10 Hybridon, Inc. Modified protein kinase a-specific oligonucleotides and methods of their use
US6624293B1 (en) * 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US7074768B2 (en) * 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
CA2283626A1 (en) * 1997-03-12 1998-09-17 Hybridon, Inc. Modified protein kinase a-specific oligonucleotides and methods of their use
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6312941B1 (en) 1997-11-26 2001-11-06 The Regents Of The University Of Michigan Compositions and methods for identifying signaling pathway agonists and antagonists
AU5618700A (en) * 1999-06-18 2001-01-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6489356B2 (en) 2000-09-05 2002-12-03 Edward Leung Method for treating pain in humans
EP1330544A4 (en) 2000-09-26 2005-04-06 Univ Duke Rna aptamers and methods for identifying the same
EP2336166A1 (en) 2000-10-12 2011-06-22 University Of Rochester Compositions that inhibit proliferation of cancer cells
KR100408916B1 (en) * 2000-11-23 2003-12-11 주식회사 바이오제니아 An anticancer drug comprising a mycolactone, an antisense Rb oligonucleotide that decreases human retinoblastoma protein expression and an anticancer drug comprising a mycolactone and the said antisense Rb oligonucleotide
US6524854B1 (en) * 2001-09-11 2003-02-25 Isis Pharmaceuticals, Inc. Antisense inhibition of PKA regulatory subunit RII alpha expression
EA010860B1 (en) 2002-02-06 2008-12-30 Викор Текнолоджиз, Инк. Anti-infarction molecules
WO2003093452A2 (en) * 2002-02-26 2003-11-13 University Of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
AU2003293412A1 (en) * 2002-12-05 2004-06-30 The Research Foundation Of State University Of Newyork HIGH EFFICACY ANTISENSE RiAlpha PKA POLY-DNP OLIGORIBONUCLEOTIDES
WO2006031210A1 (en) 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
US8029815B2 (en) * 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
US20080276327A1 (en) 2004-05-21 2008-11-06 University Of Utah Research Foundation Methods and Compositions Related to Delivery of Chemical Compounds to Invertebrate Embryos
EP1782321A4 (en) 2004-07-23 2009-11-04 Univ North Carolina Methods and materials for determining pain sensitivity and predicting and treating related disorders
US7829673B2 (en) 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
WO2007011702A2 (en) * 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
EP2392645A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
AU2007283022B2 (en) 2006-08-08 2011-07-28 Rheinische Friedrich-Wilhelms-Universitat Bonn Structure and use of 5' phosphate oligonucleotides
CA2981308C (en) 2006-09-21 2020-12-22 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic dystrophy
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
KR20090089462A (en) 2006-12-11 2009-08-21 유니버시티 오브 유타 리써치 파운데이션 Compositions and methods for treating pathologic angiogenesis and vascular permeability
US9526707B2 (en) * 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
JP2010537638A (en) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション Synthetic apolipoprotein E mimetic polypeptides and methods of use
JP2010538005A (en) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション Synthetic apolipoprotein E mimetic polypeptides and methods of use
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
CA2706317C (en) 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
WO2009137686A1 (en) 2008-05-08 2009-11-12 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
WO2010019963A2 (en) * 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
WO2010065617A1 (en) 2008-12-02 2010-06-10 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
WO2015077566A1 (en) 2013-11-21 2015-05-28 Huang Zhen Methods for structural determination of selenium derivatized nucleic acid complexes
JP7081923B2 (en) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション Higher effectiveness for removing apoE mimetic peptides and plasma cholesterol
CA2975525A1 (en) 2015-02-04 2016-08-11 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
CN107636159B (en) 2015-02-04 2022-06-14 百时美施贵宝公司 Method for selecting therapeutic molecules
MX2019001084A (en) 2016-07-28 2019-06-10 Regeneron Pharma Gpr156 variants and uses thereof.
AU2017306422A1 (en) 2016-08-03 2019-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
SG11201905508VA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hsd17b13 variants and uses thereof
US10738284B2 (en) 2017-06-05 2020-08-11 Regeneron Pharmaceuticals, Inc. B4GALT1 cDNA variants and compositions comprising the same
CN111373053A (en) 2017-09-06 2020-07-03 雷杰纳荣制药公司 Mono-immunoglobulin interleukin-1 receptor-associated molecule (SIGIRR) variants and uses thereof
KR20200062224A (en) 2017-09-07 2020-06-03 리제너론 파마슈티칼스 인코포레이티드 SLC14A1 variant and its use
MX2020003561A (en) 2017-10-11 2020-08-03 Regeneron Pharma Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation.
KR20200065045A (en) 2017-10-16 2020-06-08 리제너론 파마슈티칼스 인코포레이티드 Konulin (CRNN) variants and uses thereof
WO2021003295A1 (en) 2019-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Modulators of hsd17b13 and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
NO864301L (en) * 1986-10-28 1988-04-29 Tore Jahnsen DNA PROBLEMS FOR HUMAN REGULATORY UNIT OF CAMP-DEPENDED PROTEIN KINASES.
AU4180889A (en) * 1988-07-05 1990-02-05 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases

Also Published As

Publication number Publication date
EP0785252B1 (en) 2000-07-05
CA2488792A1 (en) 1992-05-03
KR0171210B1 (en) 1999-02-01
EP0785252A1 (en) 1997-07-23
ES2148838T3 (en) 2000-10-16
EP0490077B1 (en) 1997-08-06
US5271941A (en) 1993-12-21
CA2054325C (en) 2005-03-15
US5627158A (en) 1997-05-06
DE69127175T2 (en) 1998-03-12
DE69132299D1 (en) 2000-08-10
GR3024673T3 (en) 1997-12-31
US5691317A (en) 1997-11-25
DK0490077T3 (en) 1998-01-26
ATE156517T1 (en) 1997-08-15
ES2104644T3 (en) 1997-10-16
DE69132299T2 (en) 2001-02-15
DE69127175D1 (en) 1997-09-11
ATE194383T1 (en) 2000-07-15
GR3034535T3 (en) 2001-01-31
DK0785252T3 (en) 2000-10-02
EP0972831A1 (en) 2000-01-19
EP0490077A1 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
CA2054325A1 (en) Antisense oligonucleotides for treatment of cancer
PT101289A (en) USING TAXOL FOR THE PREPARATION OF IMPROVED EFFICACY PHARMACEUTICAL COMPOSITIONS
CA2223776A1 (en) Method of treatment for lung diseases using antisense oligonucleotides
DE3584120D1 (en) TETRAPYRROL COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
HUT59690A (en) Process for producing platinum-containing compounds against cancer and pharmaceutical compositions containing them as active components
DZ2172A1 (en) Triazole derivatives useful in therapy, process for their preparation and compositions containing them.
IL118426A (en) Pharmaceutical composition containing 1,3- bis-triazolyl-2-propanol derivative for treating cancer tumors or viruses
IL133784A (en) Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
GR3036774T3 (en) Compositions containing G-CSF and TNF binding protein.
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
HUT62785A (en) Process for producing pharmaceutical compositions comprising trinitrobenzenes and carminic acid, suitable for treating cancer and viral diseases
GB2188233B (en) Topical pharmaceutical compositions for treating vitiligo.
HUP9802536A3 (en) Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer
MD457G2 (en) New naphtiridin derivatives , preparation method, pharmaceutical compositions containing these derivatives, their utilization as antireproductive medicines
IL106763A0 (en) Pharmaceutical compositions for treating cancer
CA2097878A1 (en) Therapeutic agent for neutropenia
ZA881677B (en) Novel compounds,pharmaceutical compositions,and methods for treating inflammation and pain
GB8819626D0 (en) Pharmaceutical composition for treatment of tumours
ZA885979B (en) Skin treatment composition biospecific polymers
HUT68086A (en) Process for producing pharmaceutical compositions for treating piogene leather diseases

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed